daNIS-2: a phase III, randomized, double-blind study of the anti-TGF-β monoclonal antibody NIS793 or placebo in combination with nab-paclitaxel/gemcitabine as first-line treatment in patients with metastatic pancreatic ductal adenocarcinoma

ESMO Open · Elsevier

Аннотация

Publication date: November 2026 Source: ESMO Open, Volume 11, Issue 11 Author(s): S. Paulson, M. Ikeda, L. Shen, A. Stein, T. Macarulla, M. Milella, T. Golan, Z. Wainberg, J. Taieb, L. Wang, F. Polydoros, C. Abecunas, E. López, E.M. O’Reilly

Читать у издателя →

Похожие статьи